LaFleur, Martin W. http://orcid.org/0000-0002-5017-774X
Nguyen, Thao H.
Coxe, Matthew A.
Yates, Kathleen B. http://orcid.org/0000-0002-7383-5573
Trombley, Justin D. http://orcid.org/0000-0002-3856-3138
Weiss, Sarah A. http://orcid.org/0000-0002-4155-0346
Brown, Flavian D.
Gillis, Jacob E.
Coxe, Daniel J.
Doench, John G. http://orcid.org/0000-0002-3707-9889
Haining, W. Nicholas http://orcid.org/0000-0001-7871-3762
Sharpe, Arlene H.
Article History
Received: 30 October 2018
Accepted: 22 March 2019
First Online: 10 April 2019
Competing interests
: A.H.S. has patents on the PD-1 pathway licensed by Roche/Genentech and Novartis, and consults for Novartis. W.N.H. has a patent application on T cell exhaustion-specific enhancers. A.H.S. and W.N.H. have a patent application on PTPN2 as a therapeutic target held/submitted by Dana-Farber Cancer Institute. J.G.D. and W.N.H. consult for Tango Therapeutics. The remaining authors declare no competing interests.